hh.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The effect of snuff (smokeless tobacco) on disease activity and function in rheumatoid arthritis: experiences from the Better Anti-Rheumatic FarmacOTherapy, a longitudinal multicenter study on early rheumatoid arthritis.
Spenshult Rheumatology Hospital, Oskarström, Sweden.
Lund University, Lund, Sweden.ORCID iD: 0000-0002-6294-538X
Spenshult Rheumatology Hospital, Oskarström, Sweden.
2013 (English)In: Journal of clinical rheumatology, ISSN 1076-1608, E-ISSN 1536-7355, Vol. 19, no 1, p. 14-18Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: It is not known whether snuff (moist smokeless tobacco) affects disease activity in rheumatoid arthritis (RA).

OBJECTIVE: This study aims to study the effect of snuff on disease activity and function in Swedish patients with early RA.

METHODS: Between 1992 and 2005, 2800 adult patients were included in the Better Anti-Rheumatic FarmacOTherapy (BARFOT) early RA study in Sweden. Disease Activity Score 28 joints (DAS28), Health Assessment Questionnaire, visual analog scale for general health, and drug treatment were registered at inclusion and at follow-up after 1, 2, and 5 years. European League Against Rheumatism response and remission criteria were applied at 1 year. In 2010, a self-completed postal questionnaire was sent to 2102 patients in the BARFOT study enquiring about lifestyle factors such as smoking and use of snuff. Three controls for each patient using snuff were identified.

RESULTS: Fifty-one patients who used snuff were identified, together with 145 controls. When we adjusted for socioeconomic class, disease duration, and previous antirheumatic medication, the snuff users had lower DAS28 values at up to 6 months of follow-up than patients who had never smoked, and they had lower DAS28 values than previous smokers at up to 2 years of follow-up. No effect of snuff use on European League Against Rheumatism response was seen at up to 1 year.

CONCLUSIONS: Snuff users initially had lower DAS28 levels than never smokers and previous smokers. Copyright © 2013 by Lippincott Williams & Wilkins.

Place, publisher, year, edition, pages
Philadelphia, PA: Lippincott Williams & Wilkins, 2013. Vol. 19, no 1, p. 14-18
Keywords [en]
epidemiology, Rheumatoid arthritis, smokeless tobacco, snuff
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:hh:diva-25094DOI: 10.1097/RHU.0b013e31828214edISI: 000314615500003PubMedID: 23319018Scopus ID: 2-s2.0-84874187791OAI: oai:DiVA.org:hh-25094DiVA, id: diva2:712827
Available from: 2014-04-16 Created: 2014-04-16 Last updated: 2017-12-05Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Bergman, Stefan

Search in DiVA

By author/editor
Bergman, Stefan
In the same journal
Journal of clinical rheumatology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 145 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf